Christopher E. Rudd

Office Phone: 514-252-3400 ext.: 5878
Fax: 514-253-7626
Lab Phone: 514-252-3400 ext.:

Research Axis  Immunology-Oncology
Research Unit  Signaling mechanisms controlling the immune function of T lymphocytes


  • Full Professor 


  • B.Sc. McGill University, Montreal (1978)
  • M.Sc. University of Ottawa, Canada (1980)
  • Ph.D. University College, London (1984)
  • D.Sc. University of London, London (1999)
  • Research Fellow in Pathology, Harvard Medical School, Boston MA (1985-1987)
  •  Research Fellow in immunology, Laboratory of Immunobiology (Mentors: Ellis Reinherz,M.D. and Stuart Schlossman. M.D.), Dana Cancer Institute, Boston (1985-1986)


  • Imperial Cancer Research Fund Bursary, London, England (PhD Fellowship)(1980-1984)
  • Postdoctoral Fellowship, Cancer Research Institute, New York, USA (1985-1988)
  • Claudia Adams Barr Research Award, Boston, USA (1990-1992)
  • Cancer Research Institute/Benjamin Jacobson Family Investigator Award, New York, USA (1988-1992)
  • Scholar Award of the Leukemia Society of America, New York, USA (1993-1999)
  • Principal Research Fellowship (PRF), Wellcome Trust, London (2000-2012)
  • Wellcome Trust Distinction Award (2006)
  • MRCPath, Elected Member of the Royal College of Pathologists, London (2000-2001)
  • FRCPath, Elected Fellow of the Royal College of Pathologists, London (2001)
  • FMedSci, Elected Fellow of the Academy of Medical Sciences, London (2002)


  • The focus of my research program has been to uncover the signaling mechanisms that control T-cell immune function, and from this, to develop new strategies for the treatment of immune-based pathologies.


  • Félix Jules, Ph.D.
  • Janna Krueger, Ph.D.
  • Catherine Ménard, Ph.D.
  • Elham Ben Saad
  • Alexandra Kazanova
  • Patrick Spencer

Selected papers


  • Rudd, C. E. (2008) The reverse stop-signal model for CTLA4 function. Nat Rev Immunol 8, 153-160.
  • Raab, M., Wang, H., Lu, Y., Smith, X., Wu, Z., Strebhardt, K., Ladbury, J. E., and Rudd, C. E. (2010) T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity 32, 541-556.
  • Liu, H., Purbhoo, M. A., Davis, D. M., and Rudd, C. E. (2010) SH2 domain containing leukocyte phosphoprotein of 76-kDa (SLP-76) feedback regulation of ZAP-70 microclustering.Proc Natl Acad Sci U S A 107, 10166-10171.
  • Schneider, H., Downey, J., Smith, A., Zinselmeyer, B. H., Rush, C., Brewer, J. M., Wei, B., Hogg, N., Garside, P., and Rudd, C. E. (2006) Reversal of the TCR stop signal by CTLA-4. Science 313, 1972-1975.
  • Smith, X., Schneider, H., Kohler, K., Liu, H., Lu, Y., and Rudd, C. E. (2013) The chemokine CXCL12 generates costimulatory signals in T cells to enhance phosphorylation and clustering of the adaptor protein SLP-76. Science Signal 6, ra65.
  • Wei, B., Han, L., Abbink, T. E., Groppelli, E., Lim, D., Thaker, Y. R., Gao, W., Zhai, R., Wang, J., Lever, A., Jolly, C., Wang, H., and Rudd, C. E. (2013) Immune adaptor ADAP in T cells regulates HIV-1 transcription and cell-cell viral spread via different co-receptors. Retrovirology 10, 101.
  • Camirand, G., Wang, Y., Lu, Y., Wan, Y.Y., Lin, Y., Deng, D, Guz, G., David L. Perkins, D.L., Finn P.W, Farber, D.L., Richard A. Flavell, R., Shlomchik, W.D., Fadi G. Lakkis, F.G. Rudd, C.E. and Rothstein, D. (2014) CD45 ligation increases antigen-mediated expansion of regulatory T cells by promoting interactions with dendritic cells in vivo.  J Clin Invest. 124, 4603-13
  • Huang, Y. H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A. et al. (2015) CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517, 386-390.
  • Liu, H., Schneider, H., Recino, A., Richardson, C., Goldberg, M. W. and Rudd, C. E. (2015) The Immune Adaptor SLP-76 Binds to SUMO-RANGAP1 at Nuclear Pore Complex Filaments to Regulate Nuclear Import of Transcription Factors in T Cells.Molecular Cell 59, 840-849.
  • Taylor, A., Harker, J. A., Chanthong, K., Stevenson, P. G., Zuniga, E. I. and Rudd, C. E. (2016) Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses. Immunity 44, 274-286.
  •  Taylor A, D, Rothstein D and Rudd, C.E.  (2018) Small molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy.  Cancer Research 78, 706-717.
  • Krueger J and Rudd C.E. (2017) Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells. Immunity 46, :529-531.
  • Raab, M. Lu Y, K Smith X, Kohler, K., Smith, X., Strebhardt K, Rudd C.E. (2017) Nat Commun  LFA-1 activates focal adhesion kinases FAK1/PYK2 to generate LAT-GRB2-SKAP1 complexes that terminate T-cell conjugate formation. Nat. Commun. 8.16001.


Complete list of Dr Rudd's publications (PubMed)